Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Long-term bone mineral density response to enzyme replacement therapy in a retrospective pediatric cohort of Gaucher patients.

Ciana G, Deroma L, Franzil AM, Dardis A, Bembi B.

J Inherit Metab Dis. 2012 Nov;35(6):1101-6. doi: 10.1007/s10545-012-9476-z. Epub 2012 Mar 23.

PMID:
22441841
2.

Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.

Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T.

Blood Cells Mol Dis. 2011 Jan 15;46(1):66-72. doi: 10.1016/j.bcmd.2010.10.011. Epub 2010 Nov 26.

3.

Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.

Andersson H, Kaplan P, Kacena K, Yee J.

Pediatrics. 2008 Dec;122(6):1182-90. doi: 10.1542/peds.2007-2144.

PMID:
19047232
4.

Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.

Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN.

J Bone Miner Res. 2007 Jan;22(1):119-26.

5.

Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease - a histological study.

Rudzki Z, Okoń K, Machaczka M, Rucińska M, Papla B, Skotnicki AB.

Eur J Haematol. 2003 May;70(5):273-81.

PMID:
12694162
6.

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.

Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N.

Am J Hematol. 2017 Sep;92(9):929-939. doi: 10.1002/ajh.24801. Epub 2017 Jul 7.

7.

Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.

Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, Mardach R, Harmatz P, Hangartner T, Lee HM, Crombez E, Pastores GM.

Mol Genet Metab. 2016 Feb;117(2):164-71. doi: 10.1016/j.ymgme.2015.05.012. Epub 2015 Jun 1.

8.
9.

Bone complications in children with Gaucher disease.

Bembi B, Ciana G, Mengel E, Terk MR, Martini C, Wenstrup RJ.

Br J Radiol. 2002;75 Suppl 1:A37-44. Review.

PMID:
12036831
10.

Velaglucerase alfa for the management of type 1 Gaucher disease.

Morris JL.

Clin Ther. 2012 Feb;34(2):259-71. doi: 10.1016/j.clinthera.2011.12.017. Epub 2012 Jan 20. Review.

PMID:
22264444
11.

Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction.

Elstein D, Foldes AJ, Zahrieh D, Cohn GM, Djordjevic M, Brutaru C, Zimran A.

Blood Cells Mol Dis. 2011 Jun 15;47(1):56-61. doi: 10.1016/j.bcmd.2011.04.005. Epub 2011 May 4.

PMID:
21536468
12.

Enzyme replacement therapy with imiglucerase in a Taiwanese child with type 1 Gaucher disease.

Lin HY, Lin SP, Chuang CK, Wraith JE.

J Chin Med Assoc. 2006 May;69(5):228-32.

13.

Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.

El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK.

Mol Genet Metab. 2017 Jan - Feb;120(1-2):47-56. doi: 10.1016/j.ymgme.2016.12.001. Epub 2016 Dec 6.

14.

Body composition and bone metabolism in young Gaucher disease type I patients treated with imiglucerase.

Parisi MS, Mastaglia SR, Bagur A, Goldstein G, Zeni SN, Oliveri B.

Eur J Med Res. 2008 Jan 23;13(1):31-8.

PMID:
18226995
15.

[A retrospective study on enzyme replacement therapy in patients with Gaucher disease].

Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.

Zhonghua Er Ke Za Zhi. 2006 Sep;44(9):653-6. Chinese.

PMID:
17217655
16.

Bone marrow involvement in Gaucher disease at MRI : what long-term evolution can we expect under enzyme replacement therapy?

Fedida B, Touraine S, Stirnemann J, Belmatoug N, Laredo JD, Petrover D.

Eur Radiol. 2015 Oct;25(10):2969-75. doi: 10.1007/s00330-015-3715-2. Epub 2015 Apr 16.

PMID:
25875285
17.

Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy.

Schiffmann R, Mankin H, Dambrosia JM, Xavier RJ, Kreps C, Hill SC, Barton NW, Rosenthal DI.

Blood Cells Mol Dis. 2002 Mar-Apr;28(2):288-96.

PMID:
12064924
18.

The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).

Zimran A, Morris E, Mengel E, Kaplan P, Belmatoug N, Hughes DA, Malinova V, Heitner R, Sobreira E, Mrsić M, Granovsky-Grisaru S, Amato D, vom Dahl S.

Blood Cells Mol Dis. 2009 Nov-Dec;43(3):264-88. doi: 10.1016/j.bcmd.2009.04.003. Epub 2009 Jun 6. Review.

PMID:
19502088
19.

Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.

Stirnemann J, Rose C, Serratrice C, Dalbies F, Lidove O, Masseau A, Pers YM, Baron C, Belmatoug N.

Orphanet J Rare Dis. 2015 May 13;10:62. doi: 10.1186/s13023-015-0275-0.

20.

Evaluation of Bone Mineral Density in Patients with Type 1 Gaucher Disease in Argentina.

Larroudé MS, Aguilar G, Rossi I, Drelichman G, Fernandez Escobar N, Basack N, Slago M, Schenone A, Fynn A, Cuello MF, Fernandez R, Ruiz A, Reichel P, Guelbert N, Robledo H, Watman N, Bolesina M, Elena G, Veber SE, Pujal G, Galvan G, Chain JJ, Arizo A, Bietti J, Aznar M, Dragosky M, Marquez M, Feldman L, Muller K, Zirone S, Buchovsky G, Lanza V, Fernandez I, Jaureguiberry R, Barbieri MA, Maro A, Zarate G, Fernandez G, Rapetti M, Degano A, Kantor G, Albina A, Alvarez Bollea M, Arrocena H, Bacciedoni V, Del Rio F.

J Clin Densitom. 2016 Oct;19(4):444-449. doi: 10.1016/j.jocd.2016.07.003. Epub 2016 Aug 26.

PMID:
27574779

Supplemental Content

Support Center